1) Jacobson I. M. et al. Telaprevir for previously untreated
chronic Hepatitis C virus Infection. N Engl J Med 2011; 364: 2405-16.
2) Zeuzem S., et al. Telaprevir for retreatment of HCV infection.
N Engl J Med 2011; 364: 2417-28.
3) Sherman KE et al. Telaprevir in Combination with Peginterferon
Alfa2a and Ribavirin for 24 or 48 weeks in Treatment-Naive Genotype 1
HCV Patients who Achieved an Extended Rapid Viral Response: Final
Results of Phase 3 ILLUMINATE Study. Presentado como comunicación oral
en: The Liver Meeting of the American Association for the Study of Liver
Diseases (AASLD); 2010.
4) Centres for Disease Control and Prevention. Hepatitis C FAQs.
[citado el 17 de diciembre de 2009] Disponible en:
http://www.cdc.gov/hepatitis/C/cFAQ.htm#transmission
5) Organización Mundial de la Salud. Hepatitis C. Weekly
Epidemiological Record. 1997;72:65-69.
6) The Hepatitis C Trust. Treatments: Potential New Drugs. [citado
el 20 de febrero] Disponible en:
http://www.hepctrust.org.uk/Hepatitis_C_Info/Stages+of+Hepat...
7) McHutchison J.G. et al. Peginterferon Alfa-2b or Alfa-2a with
Ribavirin for Treatment of Hepatitis C Infection. N Engl J Med. 2009;
361: 580-93.
8) Simin M. et al. Cochrane systematic review: pegylated
interferon plus ribavirin vs. interferon plus ribavirin for chronic
hepatitis C. Alimentary Pharmacology & Therapeutics. 2007;
25(10):1153-62.
CONTACTO: CONTACTO CON LOS MEDIOS: Riqui Villarroel, ComunicaciónJanssen, Tlf.; 639890674
Andalucía
